Date: 2011-06-23
Type of
information: Halting of the trial
phase: 3
Announcement: halting of the trial
Company: Diamyd (Sweden)
Product: Diamyd® antigen based therapy
Action
mechanism:
- protein. Diamyd® is an antigen-based diabetes therapy under development to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes and other forms of autoimmune diabetes, thereby preserving the body's capacity to regulate blood sugar. The active substance in the Diamyd® diabetes vaccine is glutamic acid decarboxylase isoform 65kDa (GAD). GAD is one of the most important targets when the immune system attacks the beta cells in autoimmune diabetes. Accordingly, GAD is an autoantigen. Treatment using Diamyd® is intended to stop the autoimmune attack against the beta cells by inducing tolerance to GAD.lls.
Disease: diabetes
Therapeutic
area: Autoimmune diseases - Metabolic diseases
Country: USA
Trial
details:
Latest
news:
- Diamyd Medical AB reports that it has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd® and to initiate closure of the study.
Is
general: Yes
